Amicus Therapeutics to Announce Third Quarter 2012 Financial Results on November 5, 2012

Webcast and Conference Call at 5:00 p.m. ET

        Print
| Source: Amicus Therapeutics

CRANBURY, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Monday, November 5, 2012 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2012.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

The slide presentation for the conference call/webcast will also be available at http://ir.amicustherapeutics.com/events.cfm.

A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET on November 5, 2012. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 64424986.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.

FOLD-G

Investors/Media:
Sara Pellegrino

(609) 662-5044